Literature DB >> 22772765

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors.

A J Scheen1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22772765     DOI： 10.1007/s00125-012-2635-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

Review 1.  A review of gliptins in 2011.

Authors:  André J Scheen
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

Review 3.  Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials.

Authors:  R A DeFronzo; A H Stonehouse; J Han; M E Wintle
Journal:  Diabet Med       Date:  2010-03       Impact factor: 4.359

4.  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

Authors:  Olivia J Phung; Jennifer M Scholle; Mehak Talwar; Craig I Coleman
Journal:  JAMA       Date:  2010-04-14       Impact factor: 56.272

Review 5.  DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2011-12-22       Impact factor: 6.041

6.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Authors:  Thomas Karagiannis; Paschalis Paschos; Konstantinos Paletas; David R Matthews; Apostolos Tsapas
Journal:  BMJ       Date:  2012-03-12

7.  Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Authors:  G Schernthaner; A H Barnett; D J Betteridge; R Carmena; A Ceriello; B Charbonnel; M Hanefeld; R Lehmann; M T Malecki; R Nesto; V Pirags; A Scheen; J Seufert; A Sjohölm; A Tsatsoulis; R DeFronzo
Journal:  Diabetologia       Date:  2010-03-31       Impact factor: 10.122

8.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122
  8 in total
  1 in total

1.  ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter].

Authors:  D R Matthews; S E Inzucchi
Journal:  Diabetologia       Date:  2012-08-02       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.